A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: A southwest oncology group study

Thomas D. Brown, Phyllis Goodman, Thomas Fleming, John S. Macdonald, Evan M. Hersh, Thomas J. Braun

Research output: Contribution to journalArticle

31 Scopus citations


Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily x 5, every 14 days, at a starting dose of 150 (μg/m2/day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95% confidence interval of 0-15%.

Original languageEnglish (US)
Pages (from-to)376-378
Number of pages3
JournalJournal of Immunotherapy
Issue number5
StatePublished - Oct 1991



  • Pancreatic adenocarcinoma
  • Recombinant tumor necrosis factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this